The Killer Pseudokinase Mixed Lineage Kinase Domain-Like Protein (MLKL)
Author(s)
Murphy, JM;
Details
Publication Year 2019-11-11,Volume 12,Issue #8,Page a036376. 31712266
Journal Title
Cold Spring Harbor Perspectives in Biology
Publication Type
Journal Article
Abstract
Whereas the apoptosis cell death pathway typically enables cells to undergo death in an immunologically silent manner, cell death by necroptosis induces cell lysis and release of cellular constituents known to elicit an immune response. Consequently, the origins of necroptosis likely originated in host defense against pathogens, although recently it has emerged that dysregulation of the pathway underlies many human pathologies. The past decade has seen a rapid advance in our understanding of the molecular mechanisms underlying necroptotic cell death, including the implication of the pseudokinase, mixed lineage kinase domain-like protein (MLKL), as the terminal effector in the pathway. Here, I review our current understanding of how MLKL is activated by the upstream receptor interacting protein kinase (RIPK)3, the proposed mechanism(s) by which MLKL kills cells, and recently described layers of regulation that tune MLKL's killing activity.
Publisher
CSH Press
Research Division(s)
Inflammation
PubMed ID
31712266
NHMRC Grants
NHMRC/1105754NHMRC/1124735NHMRC/1124737
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2019-11-20 02:45:22
Last Modified: 2020-10-17 02:51:43
An error has occurred. This application may no longer respond until reloaded. Reload 🗙